<DOC>
	<DOCNO>NCT00024245</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Probenecid may increase effectiveness 10-propargyl-10-deazaaminopterin make tumor cell sensitive drug . PURPOSE : Phase I trial study effectiveness combine 10-propargyl-10-deazaaminopterin probenecid treat patient advance solid tumor .</brief_summary>
	<brief_title>10-Propargyl-10-Deazaaminopterin Plus Probenecid Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose 10-propargyl-10-deazaaminopterin probenecid patient advance solid tumor . - Determine therapeutic activity regimen patient . - Determine toxic effect regimen patient . - Determine pharmacokinetics regimen patient . OUTLINE : This dose-escalation study 10-propargyl-10-deazaaminopterin ( PDX ) probenecid . Patients receive probenecid IV PDX IV day 1 . Treatment repeat every 2 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive sequentially escalate dos probenecid PDX maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 35-40 patient accrue study .</detailed_description>
	<mesh_term>Probenecid</mesh_term>
	<mesh_term>Aminopterin</mesh_term>
	<mesh_term>10-deazaaminopterin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm cancer potentially incurable standard chemotherapy , radiotherapy , surgical procedure Failed prior firstline therapy ( patient also eligible effective firstline therapy exist ) Previously treat clinically stable brain metastasis allow No leukemia lymphoma No clinically significant pleural effusion ascites PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm^3 Platelet count least 160,000/mm^3 Hemoglobin great 10 g/dL Serum RBC folate normal Hepatic : Bilirubin great 1.5 mg/dL SGOT SGPT less 2 time upper limit normal Renal : Creatinine great 1.2 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No unstable angina No congestive heart failure No cardiac arrhythmia Other : Homocysteine normal No grade III IV edema Not pregnant nursing Fertile patient must use effective contraception 6 month study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy ( 4 week nitrosoureas mitomycin ) recover Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 3 week since prior radiotherapy bone marrowcontaining area recover Surgery : See Disease Characteristics No prior pneumonectomy Other : No concurrent folic acid potentially nephrotoxic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>